Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KNOLL ANCROD SNAKE VENOM STROKE THERAPY PHASE III TRIALS

Executive Summary

KNOLL ANCROD SNAKE VENOM STROKE THERAPY PHASE III TRIALS are under way at Westchester County Medical Center. New York Medical College (NYMC) neurologists are running the 20-month double-blind, placebo-controlled trial to study the effect of ancrod (European trade name: Arvin), made from the venom of the Malayan pit viper, on ischemic stroke victims. The study is planned to involve approximately 450 subjects at 30 U.S. and Canadian centers, of which 25 have initiated trials thus far. NYMC announced the trial May 9. Phase III trials started in August 1993.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel